{"schema_version":"secwatch.filing_event.v1","accession":"0001034842-26-000045","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2026-07-01T20:11:51+00:00","discovered_at":"2026-07-01T20:13:10.515701+00:00","generated_at":"2026-07-01T20:13:23.929763+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Rigel Pharmaceuticals appoints Alison Hannah as EVP, CMO; Lisa Rojkjaer departs","bullets":["Alison L. Hannah, M.D. appointed Executive Vice President and Chief Medical Officer effective July 1, 2026.","Dr. Hannah resigned from the Board of Directors effective July 1, 2026; she had served as a board member since May 2021.","Lisa Rojkjaer, M.D. ceased as EVP and CMO and separated from the company effective June 25, 2026.","Dr. Hannah previously served as CMO of CytomX Therapeutics and as a consultant to the pharmaceutical and biotechnology industry."],"urls":{"canonical":"https://secwatch.observer/filing/0001034842-26-000045","json":"https://secwatch.observer/filing/0001034842-26-000045.json","markdown":"https://secwatch.observer/filing/0001034842-26-000045.md","text":"https://secwatch.observer/filing/0001034842-26-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/rigl-20260625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T20:13:23.929763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c2d5e1907","claim":"Alison L. Hannah resigned as Director at RIGEL PHARMACEUTICALS INC.","evidence_excerpt":"In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6c29036265","claim":"Alison L. Hannah was appointed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.","evidence_excerpt":"On July 1, 2026, Rigel Pharmaceuticals, Inc. (the \"Company\") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e8b19684a5","claim":"Lisa Rojkjaer departed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.","evidence_excerpt":"Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Executive Vice President and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}